BlackRock
NRXP icon

BlackRock’s NRX Pharmaceuticals NRXP Stock Holding History

BlackRock’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$651K Buy
222,960
+2,500
+1% +$8.88K ﹤0.01% 4525
2026
Q2 		$902K Buy
220,460
+121,465
+123% +$401K ﹤0.01% 4387
2026
Q1 		$211K Buy
98,995
+16,341
+20% +$33K ﹤0.01% 4754
2025
Q4 		$224K Buy
82,654
+17,242
+26% +$46.3K ﹤0.01% 4695
2025
Q3 		$216K Buy
65,412
+1,012
+2% +$2.9K ﹤0.01% 4666
2025
Q2 		$210K Buy
64,400
+35,325
+121% +$88.5K ﹤0.01% 4663
2025
Q1 		$59.6K Hold
29,075
– – ﹤0.01% 4878
2024
Q4 		$64K Hold
29,075
– – ﹤0.01% 4890
2024
Q3 		$49.1K Hold
29,075
– – ﹤0.01% 4816
2024
Q2 		$70.9K Buy
29,075
+4
+0% +$14 ﹤0.01% 4784
2024
Q1 		$137K Hold
29,071
– – ﹤0.01% 4668
2023
Q4 		$134K Hold
29,071
– – ﹤0.01% 4741
2023
Q3 		$75.6K Hold
29,071
– – ﹤0.01% 4913
2023
Q2 		$141K Sell
29,071
-8,454
-23% -$50.8K ﹤0.01% 4827
2023
Q1 		$247K Buy
37,525
+272
+0.7% +$2.76K ﹤0.01% 4717
2022
Q4 		$414K Sell
37,253
-27,601
-43% -$278K ﹤0.01% 4657
2022
Q3 		$480K Sell
64,854
-378
-0.6% -$2.55K ﹤0.01% 4742
2022
Q2 		$391K Buy
65,232
+12,683
+24% +$167K ﹤0.01% 4852
2022
Q1 		$1.29M Buy
52,549
+1,004
+2% +$32.7K ﹤0.01% 4581
2021
Q4 		$2.46M Buy
+51,545
New +$3.72M ﹤0.01% 4322

Other funds holding NRXP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return
Bleakley Financial Group
Bleakley Financial Group Fairfield, New Jersey $8.8B AUM 22.37% 1-Year Est. Return

BlackRock's NRXP Position: Q3 2026 in Review

BlackRock increased its NRX Pharmaceuticals (NRXP) stake by 1.1% in Q3 2026, buying an estimated $8.88K and bringing the position to 222,960 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #4525.

BlackRock first reported a position in NRXP in Q4 2021 and has held it in 20 quarters since. The position peaked at $2.46M in Q4 2021. 33 funds tracked by Wall St. Rank hold NRXP as of Q3 2026.

  • BlackRock held 222,960 shares of NRX Pharmaceuticals worth $651K as of Q3 2026.
  • BlackRock bought 2,500 NRX Pharmaceuticals shares in Q3 2026, an estimated $8.88K.
  • NRX Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #4525 holding.
  • BlackRock first reported a position in NRX Pharmaceuticals in Q4 2021 and has held it in 20 quarters since.
  • BlackRock's NRX Pharmaceuticals position peaked at $2.46M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.